Long-term tolerability and efficacy after initial PegIFN-alpha addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study

Hjalmar Flygt; Stina Söderlund; Jesper Stentoft; Johan Richter; Perttu Koskenvesa; Satu Mustjoki; Waleed Majeed; Anna Lubking; Arta Dreimane; Berit Markevarn; Leif Stenke; Kristina Myhr Eriksson; Bjorn Tore Gjertsen; Tobias Gedde-Dahl; Andreja Dimitrijevic; Lene Udby; Ulla Olsson-Stromberg; Henrik Hjorth-Hansen

doi:10.1111/ejh.13699

Long-term tolerability and efficacy after initial PegIFN-alpha addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study

Hjalmar Flygt, Stina Söderlund, Jesper Stentoft, Johan Richter, Perttu Koskenvesa, Satu Mustjoki, Waleed Majeed, Anna Lubking, Arta Dreimane, Berit Markevarn, Leif Stenke, Kristina Myhr Eriksson, Bjorn Tore Gjertsen, Tobias Gedde-Dahl, Andreja Dimitrijevic, Lene Udby, Ulla Olsson-Stromberg, Henrik Hjorth-Hansen

Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu

Alkuperäiskieli	englanti
Lehti	European Journal of Haematology
Vuosikerta	107
Numero	6
Sivut	617-623
Sivumäärä	7
ISSN	0902-4441
DOI - pysyväislinkit	https://doi.org/10.1111/ejh.13699
Tila	Julkaistu - jouluk. 2021
OKM-julkaisutyyppi	A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Tieteenalat

3122 Syöpätaudit

Pääsy asiakirjaan

10.1111/ejh.13699

European J of Haematology - 2021 - Flygt - Long‐term tolerability and efficacy after initial PegIFN‐ addition to dasatinib (1)Lopullinen julkaistu versio, 534 KBLisenssi: CC BY-NC

Siteeraa tätä

Flygt, H., Söderlund, S., Stentoft, J., Richter, J., Koskenvesa, P., Mustjoki, S., Majeed, W., Lubking, A., Dreimane, A., Markevarn, B., Stenke, L., Myhr Eriksson, K., Gjertsen, B. T., Gedde-Dahl, T., Dimitrijevic, A., Udby, L., Olsson-Stromberg, U., & Hjorth-Hansen, H. (2021). Long-term tolerability and efficacy after initial PegIFN-alpha addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study. European Journal of Haematology, 107(6), 617-623. https://doi.org/10.1111/ejh.13699

@article{d75e6a1cfeec4de68c75734b5269f4a7,

title = "Long-term tolerability and efficacy after initial PegIFN-alpha addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study",

keywords = "BCR-ABL Positive, chronic myelogenous leukemia, clinical trial, dasatinib, interferon-alpha, CHRONIC MYELOID-LEUKEMIA, TREATMENT-FREE REMISSION, MOLECULAR RESPONSE, FRONTLINE NILOTINIB, IMATINIB, COMBINATION, INTERFERON-ALPHA-2B, SURVIVAL, PHASE-2, TRIAL, 3122 Cancers",

author = "Hjalmar Flygt and Stina S{\"o}derlund and Jesper Stentoft and Johan Richter and Perttu Koskenvesa and Satu Mustjoki and Waleed Majeed and Anna Lubking and Arta Dreimane and Berit Markevarn and Leif Stenke and {Myhr Eriksson}, Kristina and Gjertsen, {Bjorn Tore} and Tobias Gedde-Dahl and Andreja Dimitrijevic and Lene Udby and Ulla Olsson-Stromberg and Henrik Hjorth-Hansen",

year = "2021",

month = dec,

doi = "10.1111/ejh.13699",

language = "English",

volume = "107",

pages = "617--623",

journal = "European Journal of Haematology",

issn = "0902-4441",

publisher = "Wiley",

number = "6",

}

Flygt, H, Söderlund, S, Stentoft, J, Richter, J, Koskenvesa, P , Mustjoki, S, Majeed, W, Lubking, A, Dreimane, A, Markevarn, B, Stenke, L, Myhr Eriksson, K, Gjertsen, BT, Gedde-Dahl, T, Dimitrijevic, A, Udby, L, Olsson-Stromberg, U & Hjorth-Hansen, H 2021, 'Long-term tolerability and efficacy after initial PegIFN-alpha addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study', European Journal of Haematology, Vuosikerta 107, Nro 6, Sivut 617-623. https://doi.org/10.1111/ejh.13699

Long-term tolerability and efficacy after initial PegIFN-alpha addition to dasatinib in CML-CP : Five-year follow-up of the NordCML007 study. / Flygt, Hjalmar; Söderlund, Stina; Stentoft, Jesper et al.

julkaisussa: European Journal of Haematology, Vuosikerta 107, Nro 6, 12.2021, s. 617-623.

Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu

TY - JOUR

T1 - Long-term tolerability and efficacy after initial PegIFN-alpha addition to dasatinib in CML-CP

T2 - Five-year follow-up of the NordCML007 study

AU - Flygt, Hjalmar

AU - Söderlund, Stina

AU - Stentoft, Jesper

AU - Richter, Johan

AU - Koskenvesa, Perttu

AU - Mustjoki, Satu

AU - Majeed, Waleed

AU - Lubking, Anna

AU - Dreimane, Arta

AU - Markevarn, Berit

AU - Stenke, Leif

AU - Myhr Eriksson, Kristina

AU - Gjertsen, Bjorn Tore

AU - Gedde-Dahl, Tobias

AU - Dimitrijevic, Andreja

AU - Udby, Lene

AU - Olsson-Stromberg, Ulla

AU - Hjorth-Hansen, Henrik

PY - 2021/12

Y1 - 2021/12

KW - BCR-ABL Positive

KW - chronic myelogenous leukemia

KW - clinical trial

KW - dasatinib

KW - interferon-alpha

KW - CHRONIC MYELOID-LEUKEMIA

KW - TREATMENT-FREE REMISSION

KW - MOLECULAR RESPONSE

KW - FRONTLINE NILOTINIB

KW - IMATINIB

KW - COMBINATION

KW - INTERFERON-ALPHA-2B

KW - SURVIVAL

KW - PHASE-2

KW - TRIAL

KW - 3122 Cancers

U2 - 10.1111/ejh.13699

DO - 10.1111/ejh.13699

M3 - Article

VL - 107

SP - 617

EP - 623

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 6

ER -